Richard J. Willke - Concepedia

Author

Richard J. Willke

Pfizer (United States)

Also Known As

Detra Davis, Richard J Willke, Richard J. Willke, Richard Willke, Yoshiaki Uyama

106

Publications

6.3K

Citations

H-Index

127

Concepts

All Affiliations

Pfizer (United States)University of Pennsylvania University of Maryland, Baltimore Harvard University W.E. Upjohn Institute for Employment Research

About

Richard J. Willke is an author at Pfizer (United States) specializing in medicine, public health, and health policy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	3	3	65
2	Business	2	2	61
3	Education	2	2	150
4	Law	1	1	39
5	Management	1	1	23

Richard J. Willke

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making Marc L. Berger, Harold C. Sox, Richard J. Willke, Value in Health Family MedicineComparative Effectiveness ResearchHealth SystemsReal‐world Data StudiesGood Practices	2017	444
Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint <scp>ISPOR‐ISPE</scp> Special Task Force on real‐world evidence in health care decision making Marc L. Berger, Harold C. Sox, Richard J. Willke, Pharmacoepidemiology and Drug Safety	2017	331
Confidence Intervals for Cost-Effectiveness Ratios: A Comparison of Four Methods Daniel Polsky, Henry A. Glick, Richard J. Willke, Health Economics	1997	281
An Overview of Value, Perspective, and Decision Context—A Health Economics Approach: An ISPOR Special Task Force Report [2] Louis P. Garrison, Mark V. Pauly, Richard J. Willke, Value in Health Health SystemsHealthcare ValueHealth EconomicsHealth PolicyHealth Promotion	2018	182
Association between Vision Loss and Higher Medical Care Costs in Medicare Beneficiaries Jonathan C. Javitt, Zhiyuan Zhou, Richard J. Willke Ophthalmology OphthalmologyHealth EconomicsHealth PolicyHealth Care ReimbursementHealth Insurance	2007	153
A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7] Louis P. Garrison, Peter J. Neumann, Richard J. Willke, Value in Health Health Economics ApproachPublic PolicyHealthcare ValueHealth EconomicsHealth Policy	2018	152
A Health Economics Approach to US Value Assessment Frameworks—Introduction: An ISPOR Special Task Force Report [1] Peter J. Neumann, Richard J. Willke, Louis P. Garrison Value in Health Health Economics ApproachPublic PolicyHealthcare ValueHealth EconomicsHealth Policy	2018	133
Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant <i>Staphylococcus</i> Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial Zhiming Li, Richard J. Willke, Lionel Pinto, Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy	2001	129
Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative Lucinda Orsini, Marc L. Berger, William H. Crown, Value in Health Public PolicyData TrustRoad MapEducationTrust	2020	126
Estimating country-specific cost-effectiveness from multinational clinical trials Richard J. Willke, Henry A. Glick, Daniel Polsky, Health Economics	1998	124

Page 1